Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 16
- Registration Number
- NCT01186640
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 200
- Registration Number
- NCT01172418
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 852
- Registration Number
- NCT01120028
- Locations
- 🇬🇧
Oxford Radcliffe Hospitals NHS Trust, Oxford, Oxon, United Kingdom
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧University Hospitals Coventry & Warwickshire, Coventry, United Kingdom
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2010-03-09
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT01082939
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 38
- Registration Number
- NCT01019876
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Haploidentical PBMC Transplant for Severe Congenital Anemias
- Conditions
- Interventions
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2023-11-28
- Target Recruit Count
- 23
- Registration Number
- NCT00977691
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 20
- Registration Number
- NCT00951457
- Locations
- 🇦🇹
Krankenhaus der Stadt Linz, Linz, Austria
🇦🇹Universitaetsklinik f. Innere Medizin III, Salzburg, Austria
🇦🇹A.ö. Landeskrankenhaus Leoben, Leoben, Austria
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 82
- Registration Number
- NCT00943592
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 1
- Registration Number
- NCT00943293
- Locations
- 🇺🇸
The Uniiversity of Chicago, Chicago, Illinois, United States
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT00943319
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.